Head-to-head · free

Eli Lilly vs Lexeo Therapeutics, Inc. Common Stock

LLY vs LXEO — return on capital, cash generation, margins and balance sheet side by side.

LLY

2 / 3

measures where LLY leads

LXEO

1 / 3

measures where LXEO leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureLLY · FY2025LXEO · FY2025
Revenue$65.2B—
Net income$20.6B(100.0M)
Revenue growth (yearly, multi-year)23.2%—
Free cash flow—(99.0M)
Free cash flow margin——
Net cash / (debt)——
ROIC36.1%—
Return on equity101.4%-55.0%
Gross margin83.0%—
Operating margin45.6%—
Net debt / EBITDA1.25x0.59x

Figures are as reported by each company; latest fiscal year shown.

Where Eli Lilly's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full LLY profile →

Where Lexeo Therapeutics, Inc. Common Stock's cash went (FY2025)

Capital spending
$397000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full LXEO profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons